Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Expert Opinion / Cases · August 18, 2021

Met recurrence breast cancer to liver with lose of her2 in liver bx

Dr.kawyba A.A.A


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • luis betancourt

    Aug 19, 2021

    Treatment  with TE+Ciclins Inhibitors before SBRT ?

  • nagib khoury

    Sep 05, 2021

    ET  +  ABEMA   ;  better outcomes in liver metastasis and endocrine resistance vs other cdk4-6 inhibitors

  • Lee Schwartzberg

    Sep 09, 2021

    Conversion to HER2- is not too common but not rare. I have seen heterogenity in different metastatic lesions which means you may need to continue to biopsy new areas of disease. I don't typically treat 2 liver lesions with SBRT but toxicity is low and is reasonable if small lesions. I would continue OFS and switch to Fulvestrant and a CDK 4/6 inhibitor now. May get prolonged disease control. If recurs, definitely biopsy for standard biomarkers and NGS.

  • Comment deleted by User.
  • Comment deleted by Moderator.
  • Comment deleted by Moderator.
  • May 27, 2024

    Pending Moderator approval.

Further Reading